Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
Désirée van der HeijdeVibeke StrandYoshiya TanakaEdward KeystoneJoel KremerCristiano A F ZerbiniMario H CardielStanley CohenPeter NashYeong-Wook SongDana TegzováDavid GrubenGene WallensteinCarol A ConnellRoy M Fleischmannnull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2019)
Our findings indicate that clinical and radiographic treatment effects are sustained in months 12-24 in patients with RA receiving tofacitinib 5 mg or 10 mg twice daily plus MTX. The safety profile is consistent with that of other tofacitinib studies.